Adrenergic beta-2 Receptor Agonists/therapeutic use

Czira, A., Banks, V., Requena, G., Wood, R., Tritton, T., Wild, R., et al. (2024). Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B(2)-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. Bmj Open, 14, e072361. http://doi.org/10.1136/bmjopen-2023-072361
Suissa, S., Dell'Aniello, S., & Ernst, P. (2022). Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. Copd, 19, 133-141. http://doi.org/10.1080/15412555.2022.2045265
Suissa, S., Dell'Aniello, S., & Ernst, P. (2022). Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. Copd, 19, 109-117. http://doi.org/10.1080/15412555.2022.2035705